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Abstract 
 
Recent research suggests cell to cell transfer of pathogenic proteins such as tau and 
-synuclein may play a role in neurodegeneration. Pathogenic spread along neural 
pathways may give rise to specific spatial patterns of the neuronal cytoplasmic 
inclusions (NCI) characteristic of these disorders. Hence, the spatial patterns of NCI 
were compared in four tauopathies, viz., Alzheimer's disease (AD), Pick's disease 
(PiD), corticobasal degeneration (CBD), and progressive supranuclear palsy (PSP), 
two synucleinopathies, viz., dementia with Lewy bodies (DLB) and multiple system 
atrophy (MSA), the ‘fused in sarcoma’ (FUS)-immunoreactive inclusions in neuronal 
intermediate filament inclusion disease (NIFID), and the transactive response (TAR) 
DNA-binding protein (TDP-43)-immunoreactive inclusions in frontotemporal lobar 
degeneration, a TDP-43 proteinopathy (FTLD-TDP). Regardless of molecular group 
or morphology, NCI were most frequently aggregated into clusters, the clusters being 
regularly distributed parallel to the pia mater. In a significant proportion of regions, 
the regularly distributed clusters were in the size range 400 - 800m, approximating 
to the dimension of cell columns associated with the cortico-cortical pathways. The 
data suggest that cortical NCI in different disorders exhibit a similar spatial pattern in 
the cortex consistent with pathogenic spread along anatomical pathways. Hence, 
treatments designed to protect the cortex from neurodegeneration may be applicable 
across several different disorders. 
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Introduction 
 
The formation of neuronal cytoplasmic inclusions (NCI), which vary in morphology 
and molecular composition, is a characteristic feature of many neurodegenerative 
disorders (Armstrong et al 2008). These include neurofibrillary tangles (NFT) in 
Alzheimer's disease (AD) (Armstrong 1993a) and progressive supranuclear palsy 
(PSP) (Armstrong et al 2007), Pick bodies (PB) in Pick's disease (PiD) (Armstrong et 
al 1998), tau-immunoreactive neuronal inclusions in corticobasal degeneration (CBD) 
(Armstrong et al 2009), Lewy bodies (LB) in dementia with Lewy bodies (DLB) 
(Armstrong et al 1997), and NCI in multiple system atrophy (MSA) (Armstrong et al 
2006a), neuronal intermediate filament inclusion disease (NIFID) (Cairns et al 2004a, 
2004b, 2004c, Armstrong et al 2006b), and frontotemporal lobar degeneration 
(FTLD) (Armstrong et al 2010).  
 
The majority of inclusions are characterized by either abnormal aggregates of the 
microtubule-associated protein (MAP) tau (tauopathies), e.g., AD, PiD, argyrophilic 
grain disease (AGD) (Saito et al 2004), PSP, CBD, and frontotemporal dementia and 
parkinsonism linked to chromosome 17 (FTDP-17) (Reed et al 2001), or -synuclein 
(synucleinopathies), e.g., Parkinson’s disease (PD), DLB, and MSA (Goedert et al 
2001). Within the tauopathies, the molecular composition of tau varies, PiD being 
characterised by tau with three microtubule repeats (3R tau) while PSP and CBD are 
composed of four-repeat (4R) tau (Dickson 1999, Morris et al 2002). In AD, NFT are 
characterised by both 3R and 4R tau and composition also varies markedly depending 
on whether NFT are intracellular (I-NFT) or extracellular (E-NFT) (Yamaguchi et al 
1991). In addition to tau and -synuclein, other molecular pathologies have been 
recently identified. Hence, NCI in FTLD are characterised by transactive response 
(TAR) DNA-binding protein (TDP-43)-immunoreactive inclusions and therefore, 
FTLD is a TDP-43 proteinopathy (FTLD-TDP) (Neumann et al 2006, Armstrong et al 
2010) while NCI in NIFID are characterised by ‘fused in sarcoma’ (FUS)-
immunoreactivity (Yokata et al 2008, Neumann et al 2009, Armstrong et al 2011a, 
2011b). NCI also exhibit different morphologies but the majority are either flame-
shaped, e.g., NFT in AD, CBD, and PSP or globose, e.g., PiD, DLB, and NIFID. In 
contrast, a variety of inclusion morphologies are often present in FTLD-TDP 
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including rounded, spicular, or skein-like inclusions (Davidson et al 2007, Yaguchi et 
al 2004).  
 
The relationship between the various types of inclusion and the disease process itself 
is controversial. At least three hypotheses could be proposed to explain the 
relationship between the appearance of a particular inclusion and disease 
pathogenesis. First, that the pathological inclusions are the primary cause of the 
observed neurodegeneration (‘causal hypothesis’), e.g., deposition of abnormal tau or 
-synuclein may be the key event causing neuronal degeneration. Second, that the 
lesions are a consequence of neurodegenerative processes but not directly related to 
their cause (‘reaction hypothesis’), e.g., in PiD and CBD, a pathological process 
unrelated to tau deposition could cause the degeneration of neurons and result in the 
aggregation of tau. Third, inclusions could be a consequence of the 
neurodegeneration but their formation may be directly linked to the primary 
pathological mechanism (‘causal/reaction/hypothesis’). Hence, the presence of -
synuclein within cells could initiate the process of degeneration of neuronal pathways 
and then the subsequent formation of abnormal aggregates in the form of inclusions. 
 
Hardy and Gwinn-Hardy (1998) suggested that there may be relatively few cellular 
pathways leading to cell death in different disorders, and as a consequence, diseases 
classified within different molecular groups may have pathological mechanisms in 
common. Recent research suggests that pathogenic proteins such as tau and -
synuclein can be secreted from cells, enter other cells, and seed small intracellular 
aggregates within these cells (Goedert et al 2010, Steiner et al 2011). This raises the 
possibility, first suggested by Braak and colleagues with reference to PD (Hawkes et 
al 2007), that pathogenic agents may transfer along unmyelinated axons to basal areas 
of brain, the brain stem and then to the cerebral cortex. If pathogenic proteins can 
spread from cell to cell in the cortex, then the resulting NCI may exhibit a spatial 
pattern which reflects this spread. Previous studies have suggested non-random 
distributions of NCI in the cerebral cortex of various disorders, the inclusions often 
exhibiting a distinct clustering pattern (Armstrong et al 2001). The present study 
compared the spatial patterns of NCI in eight neurodegenerative disorders including 
four tauopathies (AD, PiD, CBD, PSP), two synucleinopathies (DLB, MSA), FTLD-
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TDP, and NIFID to determine whether the spatial patterns of the inclusions were 
consistent with cell to cell spread along anatomical pathways.  
 
Materials and Methods 
 
Cases 
 
With the exception of NIFID and FTLD-TDP, all cases were obtained from the Brain 
Bank, Department of Neuropathology, Institute of Psychiatry, King's College, 
London, UK. NIFID cases (N = 10) (Armstrong et al 2006b) were obtained from 
centres in Canada, Norway, Spain, Japan (one case from each), and from France, the 
UK, and the USA (two cases from each) and have been described in detail by Cairns 
et al (2004c). FTLD-TDP cases (N = 15) were obtained from Harvard Brain Tissue 
Resource Centre, Belmont, MA (2 cases), Vancouver General Hospital (6 cases), 
University of Pittsburgh (3 cases), Washington University, St Louis (3 cases), and the 
University of California, Davis (1 case) (Armstrong et al 2010). Demographic data 
and diagnostic criteria for the various disorders are listed in Table 1. Stage of disease 
was represented by neurofibrillary tangle score (range: 0, 1 - 6) (Braak et al 2006) 
with the exception of DLB in which a PD staging scale for LB was used (range: 0, 1-
6) (Braak et al 2004). 
 
Tissue preparation 
 
After death, the consent of the next of kin was obtained for brain removal, following 
local Ethical Committee procedures and the 1999 Declaration of Helsinki (as 
modified Edinburgh, 2000). Brain tissue was preserved in buffered 10% formalin or 
4% paraformaldehyde. Tissue blocks were taken from various cortical areas (Table 1) 
including the superior frontal gyrus (SFG) (B8), the superior parietal lobule (SPL) 
(B7a/7b), the inferior temporal gyrus (ITG) (B22), the parahippocampal gyrus (PHG) 
(B28), and the occipital cortex (B17). Brain material was fixed in 10% phosphate 
buffered formal-saline, and embedded in paraffin wax. Immunohistochemistry (IHC) 
was performed on 6 - 8µm sections using appropriate antibodies (Table 1). Sections 
were counterstained with haematoxylin.  
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Morphometric methods  
 
In each region of the cerebral cortex examined, NCI were counted along a strip of 
tissue (3200 to 6400µm in length) located parallel to the pia mater, using 250 x 50µm 
sample fields arranged contiguously (Armstrong 2003) (Fig 1). The sample fields 
were located both in the upper (approximating to laminae II/III) and lower 
(approximating to laminae V/VI) cortex, the short edge of the sample field being 
orientated parallel with the pia mater and aligned with guidelines marked on the slide. 
The number of NCI present in each sample field was counted.  
 
Data analysis 
 
The data were analysed by spatial pattern analysis (Armstrong 1993b, 1997, 2006, 
2007). This method uses the variance-mean ratio (V/M) to determine whether NCI 
were distributed randomly (V/M = 1), regularly (V/M < 1), or were clustered (V/M > 
1) along a strip of tissue. Counts of NCI in adjacent sample fields were added 
together successively to provide data for increasing field sizes, e.g., 50 x 250µm, 100 
x 250µm, 200 x 250µm etc., up to a size limited by the length of the strip sampled. 
V/M was then plotted against field size to determine whether the clusters of NCI were 
regularly or randomly distributed and to estimate the mean cluster size parallel to the 
tissue boundary. A V/M peak indicates the presence of regularly spaced clusters 
while an increase in V/M to an asymptotic level suggests the presence of randomly 
distributed clusters. The statistical significance of a peak was tested using 't' tests 
(Armstrong 1997). Spatial patterns of inclusions in the various regions were classified 
initially into four categories: random, uniform or regular, regularly distributed 
clusters, and large clusters (≥1600m). The frequency of regions in which regularly 
distributed clusters were in the size range 400 – 800m was also determined. In 
addition, a more complex spatial pattern was evident in some areas in which smaller 
clusters of inclusions were aggregated into large superclusters and frequency of this 
pattern was determined for each disorder. The effect of inclusion morphology, type of 
disorder, and molecular pathology on the frequency of the different types of spatial 
pattern was tested using chi-square (2) contingency table analysis.  
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In addition, the various disorders were compared using principal components analysis 
(PCA) (Armstrong et al 2010) (STATISTICA software, Statsoft Inc., 2300 East 14th 
St, Tulsa, Ok, 74104, USA). The result of a PCA is a scatter plot of the eight 
disorders in relation to the extracted PC in which the distance between disorders 
reflects their similarity or dissimilarity based on the frequency of the different types 
of spatial patterns of their respective inclusions.   
 
Finally, mean cluster size of NCI was compared between disorders using a one-way 
analysis of variance (ANOVA) (STATISTICA software, Statsoft Inc., 2300 East 14th 
St, Tulsa, Ok, 74104, USA) followed by Scheffé’s post-hoc test. In each disorder, the 
correlation (Pearson’s ‘r’) between cluster size of the inclusions, disease duration, 
and disease stage were tested. 
 
Results 
 
Examples of the spatial patterns exhibited by various NCI in different disorders are 
shown in Figs 2 - 4. Fig 2 shows a random distribution of tau-immunoreactive 
neuronal inclusions in CBD, while Fig 3 shows a small cluster of LB, approximately 
70m in diameter in DLB, and Fig 4 a larger cluster of NCI in NIFID. 
 
A comparison of the spatial patterns exhibited by the 3R tau-immunoreactive PB and 
-synuclein-immunoreactive LB in the ITG of cases of PiD and DLB respectively is 
shown in Fig 5. Both types of inclusion are distributed in regular clusters. Hence, LB 
in DLB exhibited two V/M peaks, the first at a field size of 400m and the second at 
1600m, suggesting the presence of clusters of LB, 400m in diameter, regularly 
distributed parallel to the pia mater and aggregated into larger clusters 1600m in 
diameter. By contrast, PB in PiD exhibited a single V/M peak at a field size of 
1600m suggesting regularly distributed clusters of PB, 1600m in diameter. 
 
A summary of the frequencies of the four types of spatial patterns exhibited by NCI 
in the upper and lower cortex of the eight disorders is shown in Table 2. Most 
frequently, NCI were clustered, mean cluster size being in the range 50 - 1600m, 
and the clusters were regularly distributed parallel to the pia mater. This spatial 
pattern varied in frequency in different disorders from 33% of gyri studied in MSA to 
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74% in NIFID. Larger-scale clustering, in which the NCI occurred in clusters of at 
least 1600m in diameter, but without regular spacing, was also present especially in 
PiD, CBD, and DLB. In some disorders, viz., PSP, MSA, and FTLD-TDP, the NCI 
were randomly distributed in a significant number of gyri. 
 
Chi-square (2) contingency tests (Table 2) suggested: (1) the frequency of the 
different spatial patterns of NCI was similar in the tauopathies and syncleinopathies 
(2 = 0.16, 3DF, P > 0.05), (2) within the tauopathies, the spatial pattern of the PB in 
PiD was similar to that of the NCI in CBD (2 = 2.52, 3DF, P > 0.05) but NFT in PSP 
exhibited a higher proportion of random distributions than in AD (2 = 9.47, 2DF, P < 
0.01), (3) within the tauopathies, disorders characterised by 3R tau (PiD) had similar 
spatial patterns of NCI to those characterised by 4R tau (PSP,CBD) (2 = 5.94, P > 
0.05, 3DF, P > 0.05), (4) within the synucleinopathies, there was a greater frequency 
of random distributions of NCI in MSA compared with LB in DLB (2 = 27.36, 3DF, 
P < 0.001), (5) there were significant differences in spatial patterns of NCI between 
the tauopathies and synucleinopathies compared with NIFID (2 = 13.96, 3DF, P < 
0.001) and FTLD-TDP (2 = 28.87, 3DF, P < 0.001), smaller-scale clustering being 
more frequent in the latter two disorders, and (6) spatial patterns of NCI in disorders 
with predominantly cortical flame-shaped inclusions (AD, PSP, CBD) were similar to 
those in disorders with predominantly round or oval inclusions (PiD, DLB, NIFID) 
(2 = 7.34, 3DF, P > 0.05). There were no significant differences in frequency of 
spatial patterns between upper and lower regions of the cortex. 
 
A summary of the number of regions in each disorder in which first, regularly 
distributed clusters were in the size range 400 – 800m and second, a more complex 
spatial pattern was present is shown in Table 3. In a significant proportion of gyri in 
all disorders, with the exception of MSA, the regularly distributed clusters of 
inclusions were in the size range 400 - 800m. A more complex spatial pattern in 
which smaller clusters were aggregated into larger superclusters is present in a small 
number of regions in all disorders with the exception of MSA and PSP. 
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Mean cluster size of NCI (Fig 6), averaged over all cortical areas, varied between the 
different disorders (F = 14.73, P < 0.001), post-hoc tests suggesting that: (1) cluster 
sizes were essentially similar in AD, PiD, CBD, and DLB and (2) clusters were 
significantly larger in AD, PiD, CBD, and DLB than in PSP, MSA, NIFID, and 
FTLD-TDP. No statistically significant correlations were observed between cluster 
size of inclusions and either disease duration or stage. 
 
A PCA of the data, based on the frequencies of the different types of spatial patterns, 
is shown in Fig 7. The first two PC accounted for 96% of the total variance in the 
data (PC1 = 69%, PC2 = 27%). A plot of the various disorders in relation to the first 
two PC (PC1 and PC2) suggested that spatial patterns of NCI in AD, CBD, PiD, 
DLB, and NIFID were similar, viz., in a significant proportion of regions, the 
inclusions were clustered and regularly distributed. However, in PSP and MSA the 
inclusions were also randomly distributed in a significant number of areas. FTLD-
TDP cases adopt a more intermediate position and although primarily a cortical 
disorder, also exhibited random distributions of inclusions in some gyri. 
 
Discussion  
 
Comparison between the different disorders is complicated by three factors. First, 
different antibodies were used for the various tauopathies. However, no differences in 
density, type, or morphology of NCI have been observed between the tau antibodies 
used (Armstrong et al 2001). Second, there are different pathways of spread in the 
different disorders and the regions selected for study, mainly frontal and temporal, 
may not reflect the critical regions in all disorders. In AD, for example, the entorhinal 
cortex and PHG are affected early in the disease process, the pathology then 
spreading to affect the association areas of the brain and finally the primary sensory 
regions (De lacoste and White 1993). By contrast, in PiD, early stages of the disease 
are represented by loss of neurons in the fronto-insular cortex and anterior cingulate 
gyrus while the rest of the neocortex is affected much later in the disease.  However, 
SFG, ITG, and PHG were studied in all disorders and are likely to be significantly 
affected by the relevant pathology. Third, different stages of the disease process are 
likely to be present within the various disorders. To attempt to address the effect of 
disease stage, the correlation between cluster size of inclusions and disease duration 
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and disease stage was investigated. However, the data provided little evidence that 
cluster sizes altered consistently during the disease process which could have been 
due to the small number of cases studied within each disease category.  
 
The data suggest that all types of NCI, regardless of morphology or molecular 
composition, were frequently clustered in the cortex and, in a significant proportion 
of gyri, the clusters of NCI were regularly distributed parallel to the pia mater 
(Armstrong et al 2001). The frequency of this spatial pattern varied between 
disorders, being most frequent in NIFID and AD and least common in MSA. This 
spatial pattern includes disorders which have a prominent additional glial pathology, 
e.g., CBD (Armstrong et al 2009), PSP (Armstrong et al 2007), MSA (Armstrong et 
al 2006a), and FTLD-TDP (Armstrong et al 2010) or an additional molecular 
pathology in the form of beta-amyloidosis, as in AD (Armstrong 2009b). In addition, 
the PCA suggested the disorders could be divided into two groups: (1) AD, DLB, 
PiD, CBD, and NIFID which are characterised largely by regularly distributed 
clusters of inclusions, random distributions being rare and (2) PSP and MSA, in 
which random distributions of NCI were more frequent. FTLD-TDP occupies a 
somewhat intermediate position, NCI being essentially distributed in regularly 
distributed clusters but with a significant proportion of gyri exhibiting random 
distributions.  
 
We suggest that the spatial patterns of the NCI is consistent with their development in 
association with the cells of origin of specific anatomical pathways (Armstrong 
1993a, 2008, Armstrong et al 2002) and therefore could be the result from cell to cell 
transfer of pathogenic proteins (Goedert et al 2010, Steiner et al 2011). In cortical 
regions, the cells of origin of the cortico-cortical projections are clustered and occur 
in bands which are more or less regularly distributed along the cortex. Individual 
bands of cells traverse the cortical laminae and, in the primate brain, these bands of 
cells may vary in width from 400 - 500m up to 800 - 1000µm depending on cortical 
region (Hiorns et al 1991, De Lacoste and White 1993). In a proportion of gyri, the 
width of the NCI clusters and their distribution along the cortex is consistent with an 
association with these pathways with two exceptions. Firstly, in some gyri, NCI 
occurred in significantly larger clusters, usually greater than 1600m in diameter, and 
in some regions, small clusters of NCI were aggregated into larger ‘superclusters’. 
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These results suggest that the smaller regularly distributed clusters of inclusions may 
‘coalesce’ to form larger clusters as transfer and aggregation of pathogenic proteins 
proceeds (Armstrong 1993a). Secondly, NCI are randomly distributed in some gyri 
especially in PSP and MSA and to some extent in FTLD-TDP. Random distributions 
of inclusions are usually the result of low density (Armstrong et al 2001) which is 
more likely to be the case in the cortex in PSP and MSA; primarily subcortical 
disorders (Armstrong 2006a, 2007). In contrast, FTLD-TDP is predominantly a 
cortical disorder but the NCI also exhibit random distributions in a significant 
proportion of gyri. Multiple TDP-immunoreactive pathologies including NCI, glial 
inclusions (GI), neuronal intranuclear inclusions (NII), and dystrophic neuritis (DN), 
however, are characteristic of FTLD-TDP and the density of NCI alone can be quite 
low especially in some subtypes of the disease (Armstrong et al 2010). 
 
Despite similarities in spatial pattern, there were differences in cluster sizes of NCI 
suggesting variation in the degree to which specific cortical columns are affected in 
the different diseases. Hence, the largest clusters were observed in AD, PiD, DLB, 
and CBD and the smallest in PSP, MSA, FTLD-TDP, and NIFID. In MSA and PSP, 
the small cluster size could be attributable to the largely subcortical pathology, 
cortical degeneration occurring later in the disease process (Bigio et al 1999, 
Armstrong 2006a, 2007). In FTLD-TDP and NIFID-FUS, however, clusters of NCI 
were usually 50 - 200m in diameter, significantly smaller than the estimated 
diameter of the cell columns of the cortico-cortical projections. Hence, a more 
localised pattern of cortical degeneration appears to be present in NIFID and FTLD-
TDP and there could be additional molecular pathologies that may contribute to 
cortical degeneration in these two disorders. 
 
Hence, NCI characterised by different molecular pathologies appear to be associated 
with similar spatial patterns, viz., the regularly distributed cluster of inclusions. In 
each disorder, there is the formation of a unique, abnormally aggregated, or misfolded 
protein which either causes neurodegeneration of specific anatomical pathways or 
results in a cellular response designed to sequester proteins into less harmful 
aggregates (Forman et al 2004, Armstrong 2009b, Armstrong et al 2008). A variety of 
mechanisms have been proposed by which misfolded proteins can directly affect 
cellular homeostasis including disruption of the ubiquitin degradation system, axonal 
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transport, synaptic function, and protein sequestration (Forman et al 2004). Of 
particular interest is whether the spatial patterns reflect cell to cell transfer of 
pathogenic proteins as suggested by Steiner et al. (2011). Proteins such as tau and -
synuclein can exit host cells, transfer between cells, gain access to new cells, and 
create pathology within these cells (Steiner et al 2011). For example, -synuclein 
taken up from the extracellular space can induce aggregation of other -synuclein 
proteins in recipient cells. By analogy with the scrapie form of prion protein (PrPsc), 
nucleation or seeding activity of -synuclein may result in a core of an NCI of 
transferred -synuclein surrounded by additional layers of cytoplasmic -synuclein 
contributed by the host cell. It is also possible that TDP-43 and FUS may have these 
properties and therefore, that cell to cell transfer may be a common mechanism 
determining cortical degeneration in a range of diseases.  
 
In conclusion, neurodegenerative disorders characterised by NCI expressing different 
molecular pathologies and varying in morphology exhibit similar spatial patterns in 
the cerebral cortex, consistent with an association with specific anatomical pathways. 
The data provide some support for the hypothesis of cell to cell transfer of pathogenic 
proteins and that there are common patterns of cortical neurodegeneration occurring 
across the different disorders. It would be interesting to follow the spatial pattern of 
inclusions along the anatomical pathways in the various disorders to test more 
rigorously the hypothesis of cell to cell transport. Different disorders may be 
amenable to similar interventions, e.g., immunotherapy which targets extracellular 
pathogenic proteins could lead to their removal thus preventing or slowing cell to cell 
propagation (Villolslada et al 2008).  
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Table 1. Summary of demographic details, diagnostic criteria, 
immunohistochemistry, and brain areas studied in the different disorders. 
_____________________________________________________________________ 
Disorder  N Age  M:F IHC  Diagnostic Regions 
       criteria  studied 
 
AD     6 78 (9.2) 3:3 AT8 (tau) NINCDS/ SFG, SPL, 
       ADRDA/ ITG, PHG 
       CERAD VC 
PiD     10 65.3 (11.3) 7:3 TP70 (tau) Cairns et al SFG, ITG, 
       (2007)  PHG 
 
CBD     12 64.7 (9.07) 8:4 TP007 (tau) NIH-ORD SFG, SPL, 
         ITG, PHG 
 
PSP      8 73.4 (7.4) 4:4 TP70 (tau) NINDS- SFG, ITG, 
       SPSP  PHG 
 
DLB     12 73.8 (7.2 ) 12:0 116  CDLB  SFG, ITG, 
       (-synuclein) PHG 
 
MSA     10 66.5 (8.51) 7:3 116  MCC  SFG, ITG, 
       (-synuclein) PHG 
 
NIFID     10 45.3 (12.1) 7:3 FUS  Cairns et al SFG, ITG, 
       (2007)  PHG 
 
FTLD-     15 69.6 (8.50) 7:2  TDP-43 Cairns et al SFG, ITG,  
TDP       (2007)  PHG 
____________________________________________________________________ 
Abbreviations: Alzheimer's disease (AD), Pick's disease (PiD), corticobasal 
degeneration (CBD), progressive supranuclear palsy (PSP), dementia with Lewy 
bodies (DLB), multiple system atrophy (MSA), neuronal intermediate filament 
inclusion disease (NIFID), frontotemporal lobar degeneration with TDP-43 
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proteinopathy (FTLD-TDP); FUS = ‘fused in sarcoma’ TDP-43 = transactive 
response (TAR) DNA-binding protein, N = Number of cases studied, IHC = 
Immunohistochemistry, M = Male, F = Female, SFG = Superior frontal gyrus (B8), 
SPL = Superior parietal lobule (B7a/7b), ITG = Inferior temporal gyrus (B22), PHG 
= parahippocampal gyrus (B28), VC = Visual cortex (B17). Diagnostic criteria: 
'National Institute of Neurological and Communicative Disorders and Stroke and the 
Alzheimer Disease and Related Disorders Association' (NINCDS/ADRDA) (Tierney 
et al 1988), 'Consortium to Establish a Registry of Alzheimer Disease' (CERAD) 
criteria (Mirra et al 1991); National Institute of Health-Office of rare disorders (NIH-
ORD); National Institute of Neurological Disorders and Stroke (NINDS) and the 
Society of PSP (SPSP) (NINDS-SPSP) (Hauw et al 1994, Litvan et al 1996); 
‘Consortium on Dementia with Lewy bodies' (CDLB)’ (McKeith et al 1996); 
‘Minneapolis Consensus Criteria (MCC) (Gilman et al 1998); Diagnostic criteria for 
PiD, NIFID and FTLD-TDP according to Cairns et al (2007). 
 
 
 
 
 23
Table 2. Frequency of the different types of spatial pattern (R = Random, U/RG = 
Uniform or Regular, RGC = in regularly distributed clusters, 50 – 1600m in 
diameter, LC = in large clusters, ≥1600m in diameter) exhibited by neuronal 
cytoplasmic inclusions (NCI) in the upper (U) and lower (L) cortex of various 
neurodegenerative disorders: Alzheimer's disease (AD), Pick's disease (PiD), 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), dementia 
with Lewy bodies (DLB), multiple system atrophy (MSA), neuronal intermediate 
filament inclusion disease (NIFID), frontotemporal lobar degeneration with TDP-43 
proteinopathy (FTLD-TDP), NFT = neurofibrillary tangles, PB = Pick bodies, LB = 
Lewy bodies. N = total number of regions analysed for each disorder. 
 
     Frequency of spatial pattern  
_____________________________________________________________________ 
Disorder  NCI LM N R U/RG RGC LC %RGC 
 
AD  NFT U 17 1 0 12 4 
   L 13 0 0 10 3 
   Total 30 1 0 22 7 73 
PiD  PB U 29 1 0 16 12   
   L 19 0 0 11 8   
   Total 48 1 0 27 20 53 
CBD  NCI U 43 2 1 24 16 
   L 33 0 1 24 8 
   Total 76 2 2 48 24 63 
PSP  NFT U 11 6 0 5 0 
   L 12 5 0 5 2 
   Total 23 11 0 10 2 43 
DLB  LB U 38 1 1 23 13 
   L 32 1 0 20 11 
   Total 70 2 1 43 24 61 
MSA  NCI U 6 3 0 2 1 
   L 3 2 0 1 0 
   Total 9 5 0 3 1 33 
NIFID  NCI U 27 4 1 20 2 
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   L 26 3 2 19 2 
   Total 53 7 3 39 4 74 
FTLD-TDP NCI U 30 9 0 20 1 
   L 19 9 1 7 2 
   Total 49 18 1 27 3 55 
_____________________________________________________________________ 
Chi-square (2) contingency tests comparing totals of upper and lower cortex:   
Comparing all groups: 2 = 107.78 (21DF, P < 0.001) 
Comparing tauopathies and synucleinopathies: 2 = 0.16 (3DF, P > 0.05) 
Comparing tauopathies: 2 = 55.27 (9DF, P < 0.001) 
Comparing 3R tauopathies with 4R tauopathies: 2 = 5.94 (3DF, P > 0.05) 
Comparing synucleinopathies: 2 = 27.36 (3DF, P < 0.001) 
Comparing PiD and CBD: 2 = 2.52 (3DF, P > 0.05) 
Comparing AD and PSP: 2 = 9.47 (2DF, P < 0.01) 
Comparing tauopathies and NIFID: 2 = 13.96 (3DF, P < 0.001) 
Comparing tauopathies and FTLD-TDP: 2 = 28.87 (3DF, P < 0.001) 
Comparing synucleinopathies and NIFID: 2 = 12.13 (3DF, P < 0.001) 
Comparing synucleinopathies and FTLD-TDP: 2 = 21.20 (3DF, P < 0.001) 
Comparing different morphologies: 2 = 7.34 (3DF, P > 0.05) 
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Table 3. Frequency of brain regions in which regularly distributed clusters (RGC) of  
neuronal cytoplasmic inclusions (NCI)  were either in the size range 400 – 800m or 
exhibited a more complex clustering pattern in which small clusters were aggregated 
to form larger clusters in various neurodegenerative disorders: Alzheimer's disease 
(AD), Pick's disease (PiD), corticobasal degeneration (CBD), progressive 
supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple system 
atrophy (MSA), neuronal intermediate filament inclusion disease (NIFID), 
frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP), NFT = 
neurofibrillary tangles, PB = Pick bodies, LB = Lewy bodies.  
 
Frequency of spatial pattern 
_____________________________________________________________________ 
Disorder NCI  RGC (400-800m)  Clusters/Superclusters 
 
   
AD  NFT   6    4  
PiD  PB   15    2  
CBD  NCI   24    9 
PSP  NFT   2    0  
DLB  LB   14    6  
MSA  NCI   0    0  
NIFID  NCI   11    1 
FTLD-TDP NCI   5    6  
_____________________________________________________________________ 
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Legends to figures 
 
Fig 1. Morphometric method of sampling the cerebral cortex in the various 
neurodegenerative disorders. Inclusions were counted along two strips of tissue 
parallel to the pia mater (1600 to 3200µm in length) using 50 x 250µm contiguous 
sample fields (X1 to X5 etc). The sample fields were located both in the upper and 
lower cortical laminae and extend along the gyrus from sulcus to sulcus; the short 
edge of the field being aligned with guidelines marked on the slide. 
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Fig 2. A random distribution of tau-immunoreactive neuronal inclusions in the 
tauopathy corticobasal degeneration (CBD). (tau immunohistochemistry, TP007 
antibody, haematoxylin, Bar = 80m)  
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Fig 3. A small cluster of Lewy bodies (LB), approximately 70m in diameter, in the 
synucleinopathy dementia with Lewy bodies (DLB) (-synuclein 
immunohistochemistry, 116 antibody, haematoxylin, Bar = 25m) 
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 Fig 4. A larger cluster of neuronal cytoplasmic inclusions (NCI) in neuronal 
intermediate filament inclusion disease (NIFID) NIFID (FUS immunohistochemistry, 
haematoxylin, Bar = 25m) 
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Fig 5. Pattern analysis plots showing examples of the spatial patterns exhibited by 
neuronal cytoplasmic inclusions (NCI) in the inferior temporal gyrus (ITG): A 
comparison of Lewy bodies (LB) in dementia with Lewy bodies (DLB) and Pick 
bodies (PB) in Pick's disease (PiD). Significance of V/M peaks, * P < 0.05, ** P < 
0.01.  
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Fig 6. Mean cluster size of the neuronal cytoplasmic inclusions (NCI) in the cortex of 
Alzheimer's disease (AD), Pick's disease (PiD), corticobasal degeneration (CBD), 
progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), multiple 
system atrophy (MSA), neuronal intermediate filament inclusion disease (NIFID), 
frontotemporal lobar degeneration with TDP-43 proteinopathy  (FTLD-TDP). 
Analysis of variance (ANOVA) (one-way with Scheffé’s post-hoc tests): Cluster size 
F = 14.73 (P < 0.001); Significant differences between groups: AD > PSP, NIFID, 
FTLD; PiD > PSP, NIFID, FTLD; CBD > NIFID, FTLD; DLB > PSP. 
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Fig 7. A principal components analysis (PCA) of the neurodegenerative diseases 
based on the frequency of different types of spatial pattern: Alzheimer's disease (AD), 
Pick's disease (PiD), corticobasal degeneration (C), progressive supranuclear palsy 
(PSP), dementia with Lewy bodies (D), multiple system atrophy (MSA), neuronal 
intermediate filament inclusion disease (NIFID), frontotemporal lobar degeneration 
with TDP-43 proteinopathy  (FTLD-TDP). 
 
 
 
 
